

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities, nor is it calculated to invite any such offer or invitation.



ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED

阿里健康信息技術有限公司

(Incorporated in Bermuda with limited liability)

(Stock code: 00241)

FURTHER DELAY IN DESPATCH OF CIRCULAR (1) MAJOR AND CONNECTED TRANSACTION AND (2) CONTINUING CONNECTED TRANSACTIONS

We refer to (a) the announcement of Alibaba Health Information Technology Limited (the “**Company**”) dated May 29, 2018 (the “**Announcement**”) in relation to, among other things, the Share Purchase Agreement entered into between the Company and the Vendor, pursuant to which the Company will acquire a 100% equity interest in the Target Company and (b) the announcement of the Company dated June 20, 2018 in relation to the delay in despatch of the Circular (the “**Delay Announcement**”). Unless otherwise defined, capitalized terms used in this announcement shall have the same meanings as those defined in the Announcement and the Delay Announcement.

As disclosed in the Delay Announcement, the Circular containing, among other things, further details of the Share Purchase Agreement, further details of the Framework Technical Services Agreement, further details of the Services Amendment Agreement, the advice and recommendations of the Independent Board Committee, the advice and recommendations of the Independent Financial Advisor, financial information in relation to the Target Business, together with a notice of the SGM, was expected to be

despatched to the Shareholders on or around July 6, 2018. As more time is required to finalize certain information to be included in the Circular, the Company expects that the despatch date of the Circular will be delayed to a date on or before July 13, 2018.

By Order of the Board
ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED
SHEN Difan

Chief Executive Officer and Executive Director

Hong Kong, July 6, 2018

As at the date of this announcement, the Board comprises eight Directors, of whom (i) one is an executive Director, namely Mr. SHEN Difan; (ii) four are non-executive Directors, namely Mr. WU Yongming, Mr. WANG Lei, Mr. KANG Kai and Ms. ZHANG Yu; and (iii) three are independent non-executive Directors, namely Mr. YAN Xuan, Mr. LUO Tong and Mr. WONG King On, Samuel.